A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients

BMC Gastroenterology

Volumn 9, Issue , 2009, Pages

  Idrees, Muhammad ^a   Riazuddin, Sheikh ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA; ALPHA2B INTERFERON; ANTIVIRUS AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGE; AGED; ANEMIA; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; CHRONIC HEPATITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ETHNIC DIFFERENCE; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS; HUMAN; INJECTION SITE ERYTHEMA; INSOMNIA; IRRITABILITY; LARYNGITIS; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MYALGIA; NAUSEA AND VOMITING; PRURITUS; PSYCHOSIS; RECURRENT VIRUS INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SKIN TOXICITY; SUICIDE ATTEMPT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS LOAD; COHORT ANALYSIS; DRUG ADMINISTRATION; DRUG COMBINATION; HEPATITIS C; MIDDLE AGED; PAKISTAN; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PAKISTAN; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 62149105964     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-9-5     Document Type: Article

References (27)

1. Leiveven J Pegasys/RBV Improves Fibrosis in Responders, relapsers & Nonresponders with Advanced Fibrosis 55th Annual Meeting of the American Association for the Study of Liver Disease: 2004 October 29-November 2 Boston, MA, USA
2. Alter MJ Kruszon-Moran D Nainan OV McQuillan GM Gao F Moyer LA Kaslow RA Margolis HS The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 1999, 341:556-562 10.1056/ NEJM199908193410802 10451460
3. Neumann AU Lam NP Dahari H Gretch DR Wiley TE Layden TJ Perelson AS Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 1998, 282:103-107 10.1126/ science.282.5386.103 9756471
4. McHutchison JG Gordon SC Schiff ER Shiffman ML Lee WM Rustgi VK Goodman ZD Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 1998, 339:1485-1492 10.1056/NEJM199811193392101 9819446
5. Poynard T Marcellin P Lee SS Niederau C Minuk GS Ideo G Bain V Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 1998, 352:1426-1432 10.1016/S0140-6736(98)07124-4 9807989
6. Reichard O Norkrans G Fryden A Brachonier JH Sonnerborg A Weiland O Randomized double blind, placebo controlled trial of interferon alpha 2b with and with out ribavirin for chronic hepatitis C Lancet 1998, 351:83-7 10.1016/S0140-6736(97)06088-1 9439491
7. Sim KH Wojccik JP Margulies M Wade J Heathcote J Human leukocyte antigen class II alleles may affect response of chronic hepatitis C to interferon therapy J Viral Hepat 1998, 5:249-253 10.1046/ j.1365-2893.1998.00111.x 9751011
8. Davis GL Lau JY Factorespredictive of beneficial response to therapy of hepatitis C Hepatology 1997, 26(3 Suppl 1);122S-127S 9305676 10.1002/ hep.510260721
9. Camps J Crisostomo S Garcia-Granero M Riezu-Boj JI Civeira MP Prieto J Prediction of the response of chronic hepatitis C to interferon alfa: A statistical analysis of pre-treatment variable Gut 1993, 34:1714-1717 1374469 7904252 10.1136/gut.34.12.1714
10. Hayashi J Kishihara Y Ueno K Yamaji K Kawakami Y Furusyo N Sawayama Y Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection Arch Intern Med 1998, 158:177-181 10.1001/archinte.158.2.177 9448556
11. Manns MP McHutchison JG Gordon SC Rustgi VK Shiffman M Reindollar R Goodman ZD Koury K Ling M Albrecht KJ Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial Lancet 2001, 358:958-965 10.1016/S0140-6736(01)06102-5 11583749
12. Poynard T Marcellin P Lee S Niederau C Minuk GS Ideo G Bain V Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 1998, 352:1426-1432 10.1016/ S0140-6736(98)07124-4 9807989
13. Wazir MS Majid AS Solangi GA Zuberi BF Role of interferon and interferon plus ribavirin in the management of chronic hepatitis C J Coll Phys Surgeo, Pak 2002, 12:609-612
14. Shafi MS Ahmad SI Rehana M et al Daily interferon versus interferon TIW in combination with ribavirin for treatment of chronic hepatitis C JRMC 1999, 31:20-2
15. Idrees M Development of a New HCV Genotyping Assay and its Suitability for the Detection of Common Genotypes in Hepatitis C Patients in Pakistan J Virol Meth 2008, 105:50-56 10.1016/j.jviromet.2008.03.001
16. Kwok S Higuchi R Avoiding false positives with PCR Nature 1989, 339:237-238 10.1038/339237a0 2716852
17. Khokhar N Asif N Omar S Hepatitis C virus serotype in chronic liver disease Pak J Med Sci 2002, 18(2):156-159
18. Sarrazin C Mutation within E2 and NS5A protein in patients infected with Hepatitis C Virus type 3a and correlation with treatment response Hepatology 2001, 31(6):1360-70 10.1053/jhep.2000.7987
19. John G Mc Hutchinisum Straut C Gordan Eugene RS Mitchell L Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 1998, 339:1485-1492 10.1056/ NEJM199811193392101 9819446
20. Idrees M Common genotypes of hepatitis C virus present in Pakistan Pak J Med Res 2002, 40(2):46-49
21. Shiffman ML Suter F Bacon BR Nelson D Harley H Solá R Shafran SD Barange K Lin A Soman A Zeuzem S Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3 N Engl J Med 2007, 357:124-134 10.1056/NEJMoa066403 17625124
22. Lau JYN Significance of Serum Hepatitis C Virus RNA Levels in Chronic Hepatitis C Lancet 1993, 341:1501-1504 10.1016/0140-6736(93)90635-T 8099380
23. Kanai K HCV Genotypes in Chronic Hepatitis C and Response to Interferon Lancet 1992, 339:1543 10.1016/0140-6736(92)91311-U 1351216
24. Hadziyannis SJ Sette H Jr Morgan TR Balan V Diago M Marcellin P Ramadori G Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose Ann Intern Med 2004, 140:346-355 14996676
25. Sood A Midha V Sood N Bansal M Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis Indian J Gastroenterol 2006, 25(6):283-285 17264426
26. Sulkowski MS Wasserman R Brooks L Ball L Gish R Changes in Haemoglobin during Interferon alpha-2b Plus Ribavirin Combination Therapy for Chronic Hepatitis C virus Infection J Viral Hepat 2004, 11(3):243-50 10.1111/j.1365-2893.2004.00490.x 15117326
27. Shiffman ML Side Effects of Medical Therapy for Chronic Hepatitis C Ann Hepatol 2004, 3:1-5 10 15118573